Physician profile
Paul Murray
NPI 1730183542
$2,819.98
in general payments reported to CMS, 2019-2025
24 companies · $603 in 2025
The $603 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $252 · 2020: $13.21 · 2021: $213 · 2022: $635 · 2023: $635 · 2024: $470 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,707.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,707.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $676.98 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $339.15 | 2022-2025 | Camzyos, Eliquis |
| Pfizer INC. | $255.25 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.34 | 2021-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $186.12 | 2021-2024 | Xarelto |
| Boston Scientific Corporation | $161.41 | 2019-2025 | Watchman Flx, Watchman Access System, Lux-Dx Insertable Cardiac Monitor |
| Merck Sharp & Dohme LLC | $131.13 | 2021-2025 | Verquvo |
| Medtronic, INC. | $96.33 | 2023-2024 | Corevalve Evolut R, Reveal Linq, Linq II |
| Amgen INC. | $73.54 | 2021-2025 | Repatha |
| Abbvie INC. | $68.66 | 2023-2024 | |
| Daiichi Sankyo INC. | $66.73 | 2023-2024 | Injectafer |
| Zoll Medical Corporation | $60.05 | 2019 | |
| Cardiovascular Systems INC. | $57.01 | 2019 | |
| Atricure, INC. | $54.85 | 2022-2023 | |
| Abbott Laboratories | $52.66 | 2019-2025 | Navitor |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $48.34 | 2022-2025 | Lifevest |
| Astellas Pharma US INC | $45.08 | 2019 | |
| Esperion Therapeutics, INC. | $41.66 | 2021-2022 | |
| Abiomed | $39.84 | 2022 | |
| Shockwave Medical, INC | $32.20 | 2022 | |
| Alnylam Pharmaceuticals INC. | $31.86 | 2021 | |
| Biosense Webster, INC. | $22.90 | 2024 | Carto 3 |
| Kestra Medical Technology Services, INC. | $16.38 | 2025 | Assure Wcd |
| Opsens INC. | $14.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.